COPD
Respiratory · 2007–2026
44decisions
28medicines
18carried consumer input
9individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| dupilumab Add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation (blood eosinophil count ≥ 300… | Mar 2026 | Recommended with restriction | 7 individuals Lung Foundation Australia · Pharmaceutical Society of Australia and the Centres of Excellence · Pharmaceutical Society of Australia |
| mepolizumab Add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype (blood eosinophil count… | Mar 2026 | Recommended with restriction | input received Lung Foundation Australia · Pharmaceutical Society of Australia and the Centres of Excellence · Lung Foundation · Pharmaceutical Society of Australia |
| tiotropium Long-term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD) and the prevention of COPD… | Mar 2024 | Recommended with restriction | none received |
| tiotropium Treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD) and for the treatment of severe asthma in adults and… | Nov 2024 | Recommended | input received Lung Foundation Australia |
| tiotropium with olodaterol Treatment of chronic obstructive pulmonary disease (COPD) in patients with symptoms persisting despite regular bronchodilator treatment with a LAMA or LABA, or… | Nov 2024 | Recommended | input received Lung Foundation Australia |
| budesonide with glycopyrronium and formoterol Long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients not adequately treated by a combination of an inhaled… | Jun 2023 | Recommended | 1 individuals Lung Foundation Australia |
| budesonide with formoterol Treatment of asthma in adults and adolescents aged 12 years and older, and symptomatic treatment of moderate to severe COPD in adults with FEV1 ≤50% predicted… | Nov 2023 | Recommended with restriction | input received Asthma Australia · Both Asthma Australia · Lung Foundation Australia |
| fluticasone propionate with salmeterol Treatment of asthma in patients aged 4 years or older (250/50 and 500/50 strengths), and symptomatic treatment of severe COPD in patients with a history of… | Nov 2023 | Recommended with restriction | input received Asthma Australia · Both Asthma Australia · Lung Foundation Australia |
| beclometasone dipropionate with formoterol fumarate dihydrate Symptomatic treatment of adults with severe chronic obstructive pulmonary disease (COPD) with FEV1 less than 50% predicted normal and a history of repeated… | Mar 2022 | Recommended with restriction | input received Lung Foundation |
| budesonide with glycopyrronium and formoterol Maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD) that is not adequately treated by a combination of an inhaled… | Jul 2021 | Recommended with restriction | input received Lung Foundation Australia |
| tiotropium Long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) and treatment of severe asthma in adults and children aged 6–17 years. | Jul 2020 | Recommended | 1 individuals Lung Foundation · Asthma Australia |
| tiotropium with olodaterol Chronic obstructive pulmonary disease (COPD) in patients with persistent symptoms despite regular bronchodilator treatment with a long-acting muscarinic… | Jul 2020 | Recommended | input received Lung Foundation |
| beclometasone with formoterol and glycopyrronium Maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled… | Nov 2020 | Recommended with restriction | input received Lung Foundation Australia |
| fluticasone furoate / umeclidinium / vilanterol Extension of listing for treatment of chronic obstructive pulmonary disease (COPD), specifically removal of the FEV1 <50% predicted threshold to allow use in… | Mar 2019 | Recommended with restriction | none received |
| tiotropium Chronic obstructive pulmonary disease (COPD) — long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD and prevention of COPD… | Mar 2019 | Recommended with restriction | input received Lung Foundation Australia |
| tiotropium Long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD) and for the prevention of COPD… | Mar 2019 | Noted | none received |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma in adults with frequent episodes or symptoms despite corticosteroid or ICS/LABA therapy, and treatment of COPD in adults with FEV1 <50%… | Aug 2018 | Recommended with restriction | none received |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma and chronic obstructive pulmonary disease (COPD) in patients aged 18 years and over. | Jul 2017 | Not recommended | input received |
| fluticasone furoate / umeclidinium / vilanterol Maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) less… | Dec 2017 | Recommended with restriction | input received |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma in adults aged 18 years and over with frequent asthma episodes or symptoms despite oral/inhaled corticosteroid therapy, or those requiring… | Nov 2017 | Recommended | none received |
| tiotropium bromide with olodaterol hydrochloride Chronic obstructive pulmonary disease (COPD) in patients with persistent symptoms despite regular monotherapy with a long-acting muscarinic antagonist (LAMA)… | Nov 2017 | Recommended with restriction | input received Lung Foundation Australia |
| fluticasone propionate with salmeterol xinafoate Treatment of asthma in adults with frequent episodes while receiving oral corticosteroids or optimal doses of inhaled corticosteroids, and symptomatic… | Nov 2016 | Not recommended | input received Thoracic Society of Australia · National Asthma Council Australia · Asthma Australia |
| salbutamol Treatment of asthma and chronic obstructive pulmonary disease (COPD) in patients unable to use salbutamol delivered from an oral pressurised inhalation device… | Nov 2016 | Recommended | none received |
| aclidinium bromide plus eformoterol fumarate dihydrate Treatment of chronic obstructive pulmonary disease (COPD) in patients stabilised on a combination of a long acting muscarinic antagonist and long acting beta-2… | Jul 2015 | Recommended with restriction | none received |
| tiotropium bromide plus olodaterol hydrochloride Treatment of chronic obstructive pulmonary disease (COPD) in patients stabilised on a combination of a long acting muscarinic antagonist and long acting beta-2… | Jul 2015 | Recommended with restriction | none received |
| glycopyrronium bromide COPD patients receiving combination therapy with LAB/ICS (long-acting beta-agonist and inhaled corticosteroid). | Nov 2015 | Noted | no section in document |
| fluticasone furoate / vilanterol Symptomatic treatment of chronic obstructive pulmonary disease (COPD) in patients with FEV1 less than 50% of predicted normal and a history of repeated… | Jul 2014 | Recommended with restriction | none received |
| indacaterol with glycopyrronium Once-daily maintenance bronchodilation in patients with chronic obstructive pulmonary disease (COPD) who have been stabilised on a combination of a long-acting… | Jul 2014 | Recommended with restriction | input received |
| olodaterol Maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD). | Jul 2014 | Not recommended | none received |
| umeclidinium Chronic obstructive pulmonary disease (COPD) as a long-term, once daily, maintenance bronchodilator treatment to relieve symptoms in adult patients. | Jul 2014 | Recommended with restriction | none received |
| umeclidinium + vilanterol Treatment of adult patients with chronic obstructive pulmonary disease (COPD) where symptoms persist despite regular bronchodilator treatment with a long… | Jul 2014 | Recommended with restriction | none received |
| aclidinium bromide Long-term maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). | Mar 2014 | Recommended with restriction | unclear |
| fluticasone furoate/vilanterol Symptomatic treatment of COPD in patients with FEV1 less than 50% predicted normal and a history of repeated exacerbations despite regular beta-2 agonist… | Mar 2014 | Not recommended | unclear |
| indacaterol + glycopyrronium Once-daily maintenance dual bronchodilator treatment to relieve symptoms in patients with COPD currently on LABA or LAMA monotherapy and who require additional… | Mar 2014 | Recommended with restriction | no section in document |
| umeclidinium bromide and vilanterol trifenatate Treatment of chronic obstructive pulmonary disease (COPD) in adults where symptoms persist despite regular bronchodilator treatment with a long acting… | Mar 2014 | Not recommended | no section in document |
| salbutamol Relief of bronchospasm in patients with obstructive airway disease. This submission concerns a new pack size (128 capsules) to replace the existing 100 capsule… | Nov 2014 | Recommended | no section in document |
| umeclidinium + vilanterol Long-term once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) who have… | Nov 2014 | Not recommended | unclear |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma (maintenance and SMART regimen) and chronic obstructive pulmonary disease (COPD) in adults and adolescents. | Jul 2013 | Recommended | no section in document |
| glycopyrronium bromide Once-daily maintenance bronchodilator treatment for patients with chronic obstructive pulmonary disease (COPD). | Nov 2013 | Recommended with restriction | no section in document |
| indacaterol Long-term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD). | Jul 2011 | Recommended with restriction | no section in document |
| budesonide with eformoterol fumarate dihydrate Symptomatic treatment of moderate to severe chronic obstructive pulmonary disease (COPD) where FEV1 is less than or equal to 50% predicted normal in adults… | Nov 2010 | Recommended with restriction | no section in document |
| indacaterol maleate Long-term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD). | Nov 2010 | Not recommended | no section in document |
| fluticasone propionate with salmeterol xinafoate Long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients with severe COPD (FEV1 <50% predicted normal) and a history of… | Mar 2007 | Recommended with restriction | no section in document |
| fluticasone propionate with salmeterol xinafoate Long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients with severe COPD (FEV1 <50% predicted normal) and a history of… | Mar 2007 | Recommended with restriction | no section in document |
Who spoke
Lung Foundation Australia · Lung Foundation · Asthma Australia · Both Asthma Australia · Pharmaceutical Society of Australia and the Centres of Excellence · Pharmaceutical Society of Australia · Thoracic Society of Australia · National Asthma Council Australia
What the PBS pays
$2,565M in government benefit over 2024–25, across 41,014,533 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| dupilumab | $490.8M |
| fluticasone furoate / umeclidinium / vilanterol | $218.9M |
| fluticasone furoate + vilanterol | $213.9M |
| fluticasone furoate/vilanterol | $213.9M |
| fluticasone propionate with salmeterol xinafoate | $200.6M |
| budesonide / glycopyrronium / formoterol | $155.3M |
| budesonide with glycopyrronium and formoterol | $155.3M |
| umeclidinium + vilanterol | $147.3M |
| beclometasone dipropionate with formoterol fumarate dihydrate | $126.6M |
| beclometasone dipropionate with formoterol fumarate dihydrate and glycopyrronium bromide | $126.6M |
| budesonide with eformoterol fumarate dihydrate | $102.1M |
| mepolizumab | $84.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 3 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| mepolizumabMepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils | TA1166 | recommended | 2026-06 |
| dupilumabDupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils | TA1142 | recommended | 2026-03 |
| roflumilastRoflumilast for treating chronic obstructive pulmonary disease | TA461 | recommended restricted | 2017-07 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| ethylenediamine + theophyllineDBL AMINOPHYLLINE 250mg/10mL injection ampoule | 1991 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 18 of 37 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.